EMBC logo

Embecta Corp. (EMBC)

$11.80

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on EMBC

Market cap

$690451524

EPS

1.62

P/E ratio

7.2

Price to sales

0.65

Dividend yield

5.085%

Beta

1.068758

Price on EMBC

Previous close

$11.95

Today's open

$11.95

Day's range

$11.46 - $12.11

52 week range

$9.20 - $21.23

Profile about EMBC

CEO

Devdatt (Dev) Kurdikar

Employees

2100

Headquarters

Parsippany, NJ

Exchange

Nasdaq Global Select

Shares outstanding

58512841

Issue type

Common Stock

EMBC industries and sectors

Healthcare

Medical Equipment & Supplies

News on EMBC

Embecta Growth Stalls Despite Strong Fiscal 2025 Results (Rating Downgrade)

Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume declines, and higher R&D expenses, despite improved margins and debt reduction. The dividend yield of 4.77% may appeal to income investors, but near-term growth prospects remain limited, warranting a Hold rating.

news source

Seeking Alpha • Nov 29, 2025

news preview

Meet 33 Ideal "Safer" November Small/MidCap Value DiviBuys Of The S&P600

The S&P 600 Small/MidCap index offers high-yield dividend opportunities, with 33 out of 53 top-yielding stocks meeting both the 'safer' and IDEAL dividend Dogcatcher criteria. Top ten S&P600 dividend 'dogs' are projected to deliver 24% to 93% net gains by November 2026, based on analyst targets and current yields. Stocks like KNTK, SM, CRGY, and DEI stand out for strong total return potential, but investors should beware of negative free cash flow in some high-yield picks.

news source

Seeking Alpha • Nov 26, 2025

news preview

Embecta Corp. (EMBC) Q4 2025 Earnings Call Transcript

Embecta Corp. ( EMBC ) Q4 2025 Earnings Call November 25, 2025 8:00 AM EST Company Participants Pravesh Khandelwal - VP & Head of Investor Relations Devdatt Kurdikar - President, CEO & Director Jake Elguicze - Senior VP & CFO Conference Call Participants Marie Thibault - BTIG, LLC, Research Division Michael Polark - Wolfe Research, LLC Anthony Petrone - Mizuho Securities USA LLC, Research Division Gracia Mahoney - BofA Securities, Research Division Presentation Operator Welcome, ladies and gentlemen, to Embecta Corp.'s Fiscal Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and a replay will be available on the company's website following the call.

news source

Seeking Alpha • Nov 25, 2025

news preview

Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025.

news source

GlobeNewsWire • Nov 25, 2025

news preview

embecta Announces Quarterly Cash Dividend

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2025 to stockholders of record at the close of business on December 5, 2025.

news source

GlobeNewsWire • Nov 25, 2025

news preview

EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?

Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.

news source

Zacks Investment Research • Nov 20, 2025

news preview

embecta announces changes to Board of Directors

PARSIPPANY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that David J.

news source

GlobeNewsWire • Nov 17, 2025

news preview

embecta Announces Major New Commitment to Direct Relief on World Diabetes Day

PARSIPPANY, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- On World Diabetes Day, embecta Corp. (“embecta”) (Nasdaq: EMBC), the largest manufacturer of insulin injection devices in the world, today announced a significant expansion of its partnership with Direct Relief, the leading humanitarian aid organization and largest charitable insulin provider in the United States.

news source

GlobeNewsWire • Nov 14, 2025

news preview

embecta to Report Fiscal Fourth Quarter and Full Year 2025 Financial Results

PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2025 financial results and provide an operational update, including preliminary fiscal year 2026 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 25, 2025.

news source

GlobeNewsWire • Nov 11, 2025

news preview

Meet 22 Ideal "Safer" October Small Cap DiviDogs Of The S&P600

YCharts recently began posting the entire collection of Standard and Poors Indexes: 500 Large-Caps; 400 Mid-Caps; 600 Small-Caps. This article provides an October update to the S&P600 Small-Cap Top 40 dividend dogs by yield. All 40 of current S&P600 top yield small-cap stocks pay dividends. As of 10/20/25 yields ranged 4.12%-9.32% annually. 38 by broker-target-price-estimates ranged 0.39%-53.06%. And 40 by total-annual-returns ranged 4.76%-115.12%.

news source

Seeking Alpha • Oct 22, 2025

news preview

¹ Disclosures

Get started with M1

Invest in Embecta Corp.

Open an M1 investment account to buy and sell Embecta Corp. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in EMBC on M1